ST葫芦娃(605199.SH)：全资子公司获得复方聚乙二醇（3350）电解质口服溶液药品注册证书

Core Viewpoint - ST Huluwawa (605199.SH) announced that its wholly-owned subsidiary, Guangxi Weiwei Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for the compound polyethylene glycol (3350) electrolyte oral solution, which is indicated for the treatment of chronic constipation and fecal impaction [1] Company Summary - ST Huluwawa's subsidiary Guangxi Weiwei has successfully obtained regulatory approval for a new product, enhancing its portfolio in the gastrointestinal treatment market [1] - The approved product, compound polyethylene glycol (3350) electrolyte oral solution, targets a significant health issue, chronic constipation, which may lead to increased market demand [1]